Table 2.
Values of TNF-α, IL-13, IFN-γ, HA, and LN in the groups
| Groups | TNF-α (pg/μl) | IL-13 (pg/ml) | IFN-γ (pg/μl) | HA (ng/ml) | LN (ng/ml) | |
|---|---|---|---|---|---|---|
| Model (group A) | 0.67 ± 0.04 | 129.77 ± 8.34 | 0.17 ± 0.02 | 1735.85 ± 141.49 | 1871.83 ± 52.96 | |
| Praziquantel (group B) | 0.38 ± 0.03 | 90.41 ± 5.51 | 0.42 ± 0.02 | 1061.96 ± 144.68 | 1400.74 ± 32.24 | |
| ω-3 PUFAs and praziquantel mixed (group C) | Before SEA release (group C1) | 0.27 ± 0.02 | 71.08 ± 6.21 | 0.54 ± 0.03 | 822.35 ± 69.62#,* | 1233.1 ± 42.69 |
| During SEA release (group C2) | 0.37 ± 0.02 | 86.65 ± 3.38 | 0.44 ± 0.02 | 996.79 ± 82.01 | 1334.98 ± 43.22 | |
| After SEA release (group C3) | 0.38 ± 0.02 | 88.87 ± 3.28 | 0.43 ± 0.02 | 1043.37 ± 150.78 | 1363.66 ± 42.04 | |
| Control (group D) | 0.19 ± 0.03 | 0.000 ± 0.000 | 0.72 ± 0.03 | 518.2 ± 75.56 | 1031.21 ± 83.33 | |
#
P < 0.01, compared with the model group (group A);
*
P < 0.01, compared with the praziquantel group (group B).